High-sensitivity Troponin
[High-sensitivity Troponin]
EPTIS Ringversuch Nr. 142542 | Letze Änderung 2024-05-21 | URL: https://www.eptis.bam.de/pts142542 https://www.eptis.bam.de/pts142542
| Name des Anbieters | ||||||||||
| Name des Anbieters | Weqas Weqas | |||||||||
| Ansässig in | United Kingdom | |||||||||
| Sprache(n) | ||||||||||
| Anmerkungen | High sensitivity cardiac Troponin (hs-cTn) T and I have replaced standard Troponin assays, myoglobin and Creatine kinase – MB as the preferred markers of myocardial injury. NICE diagnostic guidance – [DG40], High sensitivity troponin tests for the early rule out of NSTEMI, published in August 2020 recommended a number of hs-cTn methods that could be used for the early rule out of non-ST-segment elevation myocardial infarction (NSTEMI) in people presenting to an emergency department with chest pain and suspected acute coronary syndrome. The hsTropnin EQA programme is available as serum samples. Three liquid human serum samples are distributed monthly, with a minimum of 36 samples distributed over the year covering a wide clinical range. The samples consist of endogenous samples from patients along with a panel of linearly related samples produced from donations from healthy volunteers spiked with Cardiac Troponin. The programme includes samples at clinically relevant ranges at or near the limit of detection, samples at the 99th centiles, thresholds for early rule out and at high hs-cTn concentrations seen in myocardial infarction. The samples are distributed on a number of occasions over the year which allows for the assessment of the laboratory’s and method’s performance, including linearity, bias, within and between batch imprecision. Key Features: - Includes challenging samples at limits of detection and diagnostic “99th centile” for hs-cTnT and hs-cTnl. - Liquid human serum samples require no pre-analytical preparation. - Linearly related panel covering a clinically relevant range. For more information: https://www.weqas.com/services/eqa/hs-troponin/ or contact@weqas.com | |||||||||
| Klassifizierung | ||||||||||
| Produktgruppen |
Health care / medical devices
|
|||||||||
| Prüfgebiete |
Medical analysis
|
|||||||||
| Technische Einzelheiten | ||||||||||
|
||||||||||
| Ringversuchsziele | ||||||||||
| Zielgruppe des Ringversuchs | The Programme aims to assess the performance of organisations utilising biochemical cardiac markers to aid in the diagnosis of acute coronary syndrome (ACS) and cardiac ischaemia. | |||||||||
| Relevante Rechtsvorschriften oder Normen | Accreditation by UKAS on the basis of ISO/IEC 17043 | |||||||||
| Weitere Ziele | validation of testing methods | |||||||||
| Teilnehmerzahl | ||||||||||
| Anbieter unabhängig überprüft (akkreditiert, benannt, anerkannt) |
Akkreditiert durch UKAS auf der Grundlage von ISO/IEC 17043 |
|||||||||
| Die Durchführung des Ringversuchs ist in Auftrag gegeben durch | ||||||||||
| Kosten | ||||||||||
| Teilnahmegebühr | https://www.weqas.com/participantzone/subscription-charges/ | |||||||||
| Regelmässig durchgeführt | Ja (Frequency: Monthly. Samples: 3 x 1.0mL.) | |||||||||
| Der Ringversuch wird durchgeführt seit | 2005 | |||||||||
| Kontaktdaten des Anbieters | ||||||||||
| Anbieter | Kontaktperson | |||||||||
|
Weqas
Unit 6, Parc Ty Glas CF14 5DU Cardiff United Kingdom Telefon: 44 (0) 2920 314750 Fax: Web: http://www.weqas.com http://www.weqas.com |
Laura Lloyd-Lewis
Telefon: 44 (0) 29218 32884 Fax: E-Mail: laura.lloyd-lewis@wales.nhs.uk laura.lloyd-lewis@wales.nhs.uk |
|||||||||
Haben Sie einen Fehler entdeckt? Bitte wenden Sie sich an den zuständigen EPTIS Koordinator für United Kingdom,
Mr Savvas Xystouris.
Mr Savvas Xystouris.